0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Original Investigation |

Uveitis in Patients With Late-Stage Cutaneous Melanoma Treated With Vemurafenib

Mikael Guedj, MD1,2; Astrid Quéant, MD1,2; Elisa Funck-Brentano, MD3; Nora Kramkimel, MD2,4; Judith Lellouch, MD1; Dominique Monnet, MD, PhD1,2; Christine Longvert, MD, PhD3; Amelie Gantzer, MD3; Antoine P. Brézin, MD, PhD1,2
[+] Author Affiliations
1Department of Ophthalmology, Cochin-Hôtel-Dieu Hospital, Paris, France
2Faculté de Médecine, Université Paris Descartes, Paris, France
3Department of Dermatology, Ambroise Paré Hospital, Boulogne-Billancourt, France
4Department of Dermatology, Cochin Hospital, Paris, France
JAMA Ophthalmol. 2014;132(12):1421-1425. doi:10.1001/jamaophthalmol.2014.3024.
Text Size: A A A
Published online

Importance  This case series highlights the risk of uveitis in patients treated with vemurafenib for unresectable or metastatic cutaneous melanoma.

Objective  To assess the occurrence and severity of uveitis as an adverse effect of vemurafenib therapy.

Design, Setting, and Patients  In this observational small case series, data were collected successively from May 1, 2012, through February 31, 2013, from patients with clinical signs of ocular inflammation treated with vemurafenib at the Department of Ophthalmology, Cochin-Hôtel-Dieu Hospital.

Main Outcomes and Measures  Patients’ demographics, vemurafenib dosages, and the intervals between the onset of treatment and the first ocular symptoms were recorded. The characteristics of ocular inflammatory manifestations were analyzed. The effect of the discontinuation of vemurafenib therapy on ocular manifestations was assessed, as well as the effect of rechallenging when vemurafenib was reintroduced.

Results  Seven patients (mean [SD] age, 74.7 [4.0] years) had uveitis. The vemurafenib dose was 960 mg twice per day in 6 patients and a half dose in 1 patient. The mean (SD) time until the appearance of ocular signs was 5.6 (2.3) months (range, 19 days to 7 months), and inflammation ranged from mild or low-grade anterior uveitis to severe explosive panuveitis complicated by retinal detachment. Signs of ocular inflammation were always bilateral. Optical coherence tomography revealed a macular edema in only 1 of the 7 patients. Clinical improvement occurred when vemurafenib therapy was stopped in 5 of 7 patients. The rechallenge at treatment reintroduction was positive in 2 of 7 patients.

Conclusions and Relevance  This small case series highlights that uveitis can be a noteworthy adverse effect of vemurafenib therapy in patients with metastatic cutaneous melanoma. However, these cases of uveitis were usually restricted to the anterior segment and manageable with local corticosteroid therapy, which justified the continuation of vemurafenib therapy because the benefits regarding the patients’ survival were greater than the risk to their vision.

Figures in this Article

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Place holder to copy figure label and caption
Figure 1.
Clinical Presentation of Uveitis in Patient 5

A, Nongranulomatous anterior uveitis 3 weeks after vemurafenib treatment onset. In the left eye, pigment deposits are seen on the anterior capsule at the site of synechiae, which were subsequently broken. B, Vitritis (anterior chamber cells [4+]) in the left eye; optic disc edema is seen through the dense vitreous haze.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.
Clinical Presentation of Uveitis in Patient 6

Nongranulomatous anterior uveitis in the left eye 7 months after onset of vemurafenib treatment. The intense inflammation resulted in posterior synechiae, some of which remained despite the mydriatic and corticosteroid local treatment.

Graphic Jump Location

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Jobs
brightcove.createExperiences();